Insights on pharma trends and real-world AI applications in life sciences
Genentech, a member of the Roche Group, recently announced breakthrough positive results from its global Phase 3 clinical study (Krascendo 1) evaluating divarasib, its next-generation, highly selective KRAS G12C inhibitor.
Sarepta Therapeutics (NASDAQ: SRPT) recently announced that the U.S. Food and Drug Administration (FDA) has officially accepted its Supplemental New Drug Applications (sNDAs) for AMONDYS 45® (casimersen) and VYONDYS 53® (golodirsen), its antisense oligonucleotide exon-skipping therapies for Duchenne muscular dystrophy (DMD).
On June 30, 2026, clinical-stage biopharmaceutical company AC Immune announced 12-month interim data from the Phase 1b/2 ABATE trial of ACI-24, its investigational anti-amyloid beta (Aβ) active immunotherapy for prodromal Alzheimer’s disease (AD). Designed to train the human immune system to autonomously identify and clear pathogenic proteins, ACI-24 demonstrated a favorable safety profile and a clear dose-response relationship in this trial
Alexion, AstraZeneca Rare Disease, presented the latest results from its global Phase 3 clinical program for the next-generation enzyme replacement therapy, efzimfotase alfa (ALXN1850). Data from the studies demonstrate that in treatment-naïve pediatric patients, the therapy not only met its primary endpoints but also yielded positive results across multiple dimensions, including bone health, physical function, quality of life, and safety.
On June 26, 2026, clinical-stage biotechnology company Epicrispr Biotechnologies announced promising interim results from its ongoing Phase 1/2 first-in-human study of EPI-321, an investigational epigenetic gene therapy for facioscapulohumeral muscular dystrophy (FSHD).
On June 24, 2026, clinical-stage biotechnology company Wave Life Sciences announced the initiation of the Phase 2a clinical study (INLIGHT™ trial) for WVE-007, an innovative GalNAc-siRNA therapy targeting obesity and cardiometabolic diseases. Distinguishing itself from conventional treatments, WVE-007 modulates gene expression to achieve a promising profile of "fat loss without muscle loss" combined with the potential for infrequent, long-term dosing.
Corxel Pharmaceuticals announced positive topline results from its U.S. Phase 2 clinical trial of CX11, an oral small molecule GLP-1 receptor agonist (GLP-1 RA). The data demonstrate that the drug achieved up to an 11.5% reduction in body weight after 36 weeks of treatment, while maintaining a favorable gastrointestinal (GI) tolerability profile and hepatic safety.
On June 22, 2026, REGENXBIO announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) regarding the regulatory pathway for NAVSUNLI™ (RGX-121), its gene therapy candidate for Hunter syndrome (Mucopolysaccharidosis II, or MPS II).
On June 18, 2026, F2G and Shionogi jointly announced positive topline data from the global Phase 3 OASIS study. The results demonstrate that olorofim, an investigational oral antifungal drug, shows clinical efficacy non-inferior to current gold-standard therapies in patients with invasive aspergillosis, while offering significant advantages in safety and convenience of administration.
On June 17, 2026, biotechnology company uniQure announced a major regulatory breakthrough following a recent Type B meeting with the U.S. Food and Drug Administration (FDA). The FDA confirmed that the 3-year analysis from the Phase I/II study of AMT-130, a gene therapy for Huntington’s disease (HD), would be acceptable as the primary basis for a Biologics License Application (BLA) under the accelerated approval pathway.
On June 16, 2026, Edgewise Therapeutics announced positive top-line results from its Phase 2 CIRRUS-HCM study. The data demonstrate that EDG-7500, a next-generation cardiac sarcomere modulator, exhibits clinical efficacy in both obstructive (oHCM) and nonobstructive (nHCM) patients.
At the Endocrine Society’s Annual Meeting (ENDO 2026) held recently in Chicago, Rhythm Pharmaceuticals, a biopharmaceutical company focused on rare neuroendocrine diseases, presented a series of high-impact clinical data. The findings highlight the significant potential of its core MC4R agonist portfolio in treating acquired hypothalamic obesity (HO), Bardet-Biedl syndrome (BBS), and Prader-Willi syndrome (PWS).
5 min